Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Hannah Fuchs

Hannah Fuchs

DPhil Student

Research interests

Oesophageal cancer has a poor prognosis and a rising incidence particularly in Western countries. The LUD2015-005 Trial is a Phase 1/2 study that investigates the merit of immunotherapy for oesophageal cancer patients. Immunotherapy has revolutionised the treatment of many cancers, such as melanoma, but only a fraction of patients with oesophageal cancer seem to respond to this therapy. By analysing patient samples from the LUD2015-005 trial, my research therefore aims to contribute to an understanding why some patients respond to immunotherapy and some do not, and if there is a way to predict who will respond. To this end I will be studying the role of certain immune cells and molecules, both within the tumour and in the blood in patients pre- and post-therapy. If successful, this work will help identify patients that will likely respond to immunotherapy or need further treatment and follow-up.


My research is funded by Cancer Research UK as part of their DPhil Cancer Science programme. Prior to starting at the Ludwig Institute, I have studied Medicine for four years at Oxford and will complete my final two years after my DPhil. In my studies I specialised in Immunology and Molecular Pathology. For my intercalated BSc I was involved in researching the role of inflammation in the blood-forming bone marrow microenvironment in children with Trisomy 21, who are predisposed to developing childhood leukaemia, with the Roberts lab in the Weatherall Institute of Molecular Medicine. I have also gained additional research experience in the Centre of Translational Cell Research in Freiburg (Germany), and have been involved in trials with the Asymptomatic Covid-19 Staff Testing Team at the JR Hospital here in Oxford. Combining both medicine and science in my training will put me in a good position to positively impact the lives of cancer patients, and to pursue both my passion for the clinic and research.